Cargando…
THU326 Subcutaneous Insulin Aspart Every 4 Hours In the Treatment Of COVID-19 Patients With Diabetic Ketoacidosis: A Retrospective Study
Disclosure: D. Chiewchalermsri: None. C. Wanittansirichok: None. C. Sriphrapradang: None. SUBCUTANEOUS INSULIN ASPART EVERY 4 HOURS IN THE TREATMENT OF COVID-19 PATIENTS WITH DIABETIC KETOACIDOSIS: A RETROSPECTIVE STUDY Introduction: COVID-19 infection increases the risk of diabetic ketoacidosis (DK...
Autores principales: | Chiewchalermsri, Dararat, Wanittansirichok, Chayanin, Sriphrapradang, Chutintorn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553442/ http://dx.doi.org/10.1210/jendso/bvad114.760 |
Ejemplares similares
-
THU328 Appropriate Initial Insulin Dosage For Management Of Steroid-induced Hyperglycemia In Hospitalized COVID-19 Patients
por: Ketaroonrut, Nuttavadee, et al.
Publicado: (2023) -
THU260 Development Of Plantar Thermography For Screening Of Diabetic Neuropathy
por: Panamonta, Vipawee, et al.
Publicado: (2023) -
THU310 A Presentation Of Diabetic Ketoacidosis In Gestational Diabetes
por: Yim, Carly, et al.
Publicado: (2023) -
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023) -
THU386 Non-diabetic Ketoacidosis As A Rare Complication Of Colitis And Gastritis
por: Bosques-Lorenzo, Jaymilitte, et al.
Publicado: (2023)